LUZELLE CABUNTALA: Open Payments
NPI 1235966177 · HENDERSON, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,557 in 99 payments from 19 companies in 2025. Trend: 2023 $0 · 2024 $252 · 2025 $2,557
Food & beverage: $2,480Education: $77
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 18 | $575 |
| ABBVIE INC. | 14 | $334 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $277 |
| Phathom Pharmaceuticals, Inc. | 9 | $227 |
| GENZYME CORPORATION | 15 | $220 |
| Gilead Sciences, Inc. | 9 | $219 |
| Novo Nordisk Inc | 4 | $162 |
| Aimmune Therapeutics, Inc. | 1 | $110 |
| Intra-Sana Laboratories | 4 | $97 |
| Lilly USA, LLC | 2 | $54 |
Products named: TREMFYA, XIFAXAN, DUPIXENT, VOQUEZNA, SKYRIZI, Wegovy, RINVOQ, ZENPEP.
Industry payments across NV — which companies pay providers there.
